The dedication of these charities, set up when a family has been touched by cancer, drives forward our research immeasurably. We are so grateful to work with such passionate organisations and receive their generous support.
Alice's Arc supports our vital rhabdomyosarcoma (RMS) research at the ICR - an extremely aggressive and the most common type of sarcoma found in the soft tissues of children - working to develop kinder treatments that are more effective and with fewer side-effects.
Support from Abbie’s Army is making a huge contribution towards our research into DIPG (diffuse intrinsic pontine glioma).
The Chris Lucas Trust has so far raised over £1 million for research into rhabdomyosarcoma at the ICR and continue to fundraise through flagship events such as the Great North Bike Ride.
Christopher Smile has raised in excess of £1 million for childhood cancer research. Their funding has been used to support four full-time research positions at the ICR.
Lucas’ Legacy is raising funds and awareness to improve the outlook for children with brain tumours.
The Tom Bowdidge Foundation was founded in 2014 in memory of Tom who died of Desmoplastic Small Round Cell Tumour (DSRCT) in 2013. The Foundation has pledged to give more than £250,000 towards funding research at the ICR.
Abbie’s Fund was set up in 2005 by Claire Attard and Lori Wormald, for Abbie Shaw who died of cancer the following year, aged 5. Abbie’s Fund has raised over £300,000, which has helped fund our research into treatment for neuroblastoma.
Rob’s ARTTT is committed to finding a cure for teenage cancer, and they have raised over £240,000 for DSRCT research to date.
Vidhu and Somnath Menon have set up The Rudy A Menon Foundation to fund research into Gliomatosis Cerebri and other rare brain cancers. Their son, Rudy, died from brain cancer in 2013, aged 26.
The Kelly Turner Foundation was set up by Martin and Linda, in memory of their daughter Kelly who died of DSRCT in 2017, aged 17. Through their remarkable efforts, they have already raised over £600,000 towards our research to improve the outlook for patients with this cancer.